NEW YORK, and AMSTERDAM and OXFORD, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop ...

- The United States Food and Drug Administration cleared the investigational new drug application for VLS-01 (buccal film DMT); atai expects to initiate a Phase 2 study in treatment-resistant ...

VLS-01, a proprietary oral transmucosal film (OTF) formulation of DMT, was well-tolerated with a favorable safety profile Pharmacokinetic and pharmacodynamic data confirmed systemic delivery of DMT ...

Initial BPL-003 (intranasal 5-MeO-DMT) Phase 2a open-label results demonstrated a rapid and durable antidepressant effect through three months in TRD patients; top-line results from a controlled Phase ...

Atai Life Sciences (NASDAQ: ATAI), a biotech focused on developing psychedelic-based medicines to treat mental health disorders, was a standout stock over the past few days in its rather limited peer ...

Some of Wall Street’s biggest upside calls are not sitting in the mega-cap names. They are hiding in small, volatile stocks ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even ...

That drug, tagged BPL-003 by Atai, is an antidepressant that was recently evaluated in an open-label phase 2a study. The company is developing the medication in collaboration with a privately held ...

NEW YORK and BERLIN, May 29, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company on a mission to develop highly effective ...

The biotech earned an important fast-track review designation from a major regulator. This should speed the development (and potentially, commercialization) of one of its investigational treatments.